Personalized approach in optimizing the treatment of acute pancreatitis

Materialy VIII Vserossijskoj konferencii s mezhdunarodnym uchastiem «Mediko-fiziologicheskie problemy jekologii cheloveka» Pub Date : 2021-12-13 DOI:10.34014/mpphe.2021-60-62

A. P. Vlasov, V. A. Trofimov, S. Al'-Kubaysi, N. Myshkina, T. A. Muratova, L. N. Umnov, M. Khachaturov

{"title":"Personalized approach in optimizing the treatment of acute pancreatitis","authors":"A. P. Vlasov, V. A. Trofimov, S. Al'-Kubaysi, N. Myshkina, T. A. Muratova, L. N. Umnov, M. Khachaturov","doi":"10.34014/mpphe.2021-60-62","DOIUrl":null,"url":null,"abstract":"In order to determine the effectiveness of the use of remaxol based on a personalized approach in patients with acute pancreatitis, based on the establishment of gene polymorphism of integrin beta-3 (T1565C, ITGB3), integrin alpha-2 (C807T, ITGA2), fibrinogen (G(-455)A, FGB) and plasminogen activator inhibitor (5G(-675)4G, SERPINE1), a study of 84 patients with acute pancreatitis of varying severity was conducted. As a result of the study, it was proved that in order to increase the effectiveness of treatment of patients with severe acute pancreatitis upon admission, in addition to clinical, laboratory and instrumental studies, it is necessary to conduct genetic testing of the genotypes of the polymorphism of the GPIIa gene (T1565C), ITGA2 (C807T), FGB (G(-455)A) and SERPINE1 (5G(-675)4G) to develop a personalized approach in the treatment of this severe category of patients. \nKey words: acute pancreatitis, genotype, DNA diagnostics, genetic testing of genotypes, personalized medicine.","PeriodicalId":378573,"journal":{"name":"Materialy VIII Vserossijskoj konferencii s mezhdunarodnym uchastiem «Mediko-fiziologicheskie problemy jekologii cheloveka»","volume":"38 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Materialy VIII Vserossijskoj konferencii s mezhdunarodnym uchastiem «Mediko-fiziologicheskie problemy jekologii cheloveka»","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.34014/mpphe.2021-60-62","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 0

Abstract

In order to determine the effectiveness of the use of remaxol based on a personalized approach in patients with acute pancreatitis, based on the establishment of gene polymorphism of integrin beta-3 (T1565C, ITGB3), integrin alpha-2 (C807T, ITGA2), fibrinogen (G(-455)A, FGB) and plasminogen activator inhibitor (5G(-675)4G, SERPINE1), a study of 84 patients with acute pancreatitis of varying severity was conducted. As a result of the study, it was proved that in order to increase the effectiveness of treatment of patients with severe acute pancreatitis upon admission, in addition to clinical, laboratory and instrumental studies, it is necessary to conduct genetic testing of the genotypes of the polymorphism of the GPIIa gene (T1565C), ITGA2 (C807T), FGB (G(-455)A) and SERPINE1 (5G(-675)4G) to develop a personalized approach in the treatment of this severe category of patients. Key words: acute pancreatitis, genotype, DNA diagnostics, genetic testing of genotypes, personalized medicine.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

个性化方法优化急性胰腺炎的治疗

为了确定基于个体化方法的瑞美索在急性胰腺炎患者中的应用效果，在建立整合素β -3 (T1565C、ITGB3)、整合素α -2 (C807T、ITGA2)、纤维蛋白原(G(-455) a、FGB)和纤溶酶原激活物抑制剂(5G(-675)4G、SERPINE1)基因多态性的基础上，对84例不同严重程度的急性胰腺炎患者进行了研究。本研究结果证明，为了提高重症急性胰腺炎患者入院时的治疗效果，除临床、实验室和仪器研究外，还需要对GPIIa基因(T1565C)、ITGA2 (C807T)、FGB (G(-455) a)和SERPINE1 (5G(-675)4G)的多态性基因型进行基因检测，以制定治疗这类重症患者的个性化方法。关键词:急性胰腺炎，基因型，DNA诊断，基因型基因检测，个体化治疗

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Materialy VIII Vserossijskoj konferencii s mezhdunarodnym uchastiem «Mediko-fiziologicheskie problemy jekologii cheloveka»

自引率

0.00%

发文量